NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Tan Tock Seng Hospital
Conditions: Influenza Vaccination
Interventions: Flublok Quadrivalent vaccine, Fluarix Quadrivalent vaccine, Flucelvax Quadrivalent vaccine
Countries: Singapore
This study is a prospective randomised trial of 3 influenza vaccine formulations with different manufacturing processes: 1) egg-grown (QIV-E); 2) cell-grown (QIV-C); and 3) recombinant protein (QIV-R). The main objective is to compare the antibody responses following influenza vaccination among these 3 vaccines to determine whether recombinant vaccines offer superior protection over standard egg or cell-based formulations. The attenuating effects of prior vaccination on vaccine immunogenicity will also be evaluated. Hypothesis: Vaccination with recombinant vaccine results in better antibody responses, particularly against A(H3N2) viruses, than either standard egg-grown vaccines or cell-grown vaccines.
Sex: ALL
Age: 21 Years to 49 Years
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Inclusion Criteria: * Able to provide informed consent * Willing and able to provide 4 blood samples at D0, 14, 150 and 330 post-vaccination * Has not received influenza vaccine for at least 6 months * Willing to provide current mobile phone number for SMS reminders Exclusion Criteria: * Known contraindication(s) for QIV (e.g. hypersensitivity to vaccine component (including eggs)). * Recently (last 7 days) or currently ill or has a fever above 38 degrees celsius * Cannot recall if they were vaccinated against influenza during more or less than two of the preceding five years. Vaccinated during two of the preceding five years. * Hypogammaglobulinaemia on immunoglobulin replacement * Undergoing immunosuppressive therapies including corticosteroids
- Singapore, Singapore, Singapore